A recent study by Charles River Associates reveals inequities in access to treatment for multiple sclerosis (MS) across Europe. A summary of key findings, with a link to the full report, can be found at the link below.
The socioeconomic impact of rare diseases: An analysis of the evidence in middle-income countries
Worldwide, it is estimated that over 300 million people are living with one or more of the 6,000 to 8,000 identified rare conditions, yet the impact of rare...